0	3	Two	two	CD
4	18	glucocorticoid	glucocorticoid	NN
19	26	binding	binding	NN
27	32	sites	site	NNS
33	35	on	on	IN
36	39	the	the	DT
40	45	human	human	JJ
46	60	glucocorticoid	glucocorticoid	NN
61	69	receptor	receptor	NN
69	70	.	.	.

72	87	Glucocorticoids	glucocorticoid	NNS
88	91	are	be	VBP
92	97	known	know	VBN
98	100	to	to	TO
101	105	have	have	VB
106	107	a	a	DT
108	113	lytic	lytic	JJ
114	120	effect	effect	NN
121	123	in	in	IN
124	132	leukemic	leukemic	JJ
133	138	cells	cell	NNS
139	142	via	via	IN
143	155	interactions	interaction	NNS
156	160	with	with	IN
161	164	the	the	DT
165	179	glucocorticoid	glucocorticoid	NN
180	188	receptor	receptor	NN
189	190	(	(	(
190	192	GR	GR	NNP
192	193	)	)	)
193	194	.	.	.

195	203	Cortisol	Cortisol	NNP
204	207	and	and	CC
208	215	various	various	JJ
216	225	synthetic	synthetic	JJ
226	241	glucocorticoids	glucocorticoid	NNS
242	246	bind	bind	VBP
247	249	to	to	TO
250	253	the	the	DT
254	256	GR	gr	NN
257	261	with	with	IN
262	270	one-site	one-site	JJ
271	279	kinetics	kinetic	NNS
279	280	.	.	.

281	291	Cortivazol	Cortivazol	NNP
292	293	(	(	(
293	296	CVZ	CVZ	NNP
296	297	)	)	)
298	300	is	be	VBZ
301	302	a	a	DT
303	309	unique	unique	JJ
309	310	,	,	,
311	315	high	high	JJ
316	323	potency	potency	NN
324	333	synthetic	synthetic	JJ
334	348	glucocorticoid	glucocorticoid	NN
348	349	,	,	,
350	355	which	which	WDT
356	359	has	have	VBZ
360	361	a	a	DT
362	375	phenylpyrazol	phenylpyrazol	NN
376	381	fused	fuse	VBN
382	384	to	to	TO
385	388	the	the	DT
389	395	A-ring	a-ring	NN
396	398	of	of	IN
399	402	the	the	DT
403	410	steroid	steroid	NN
411	418	nucleus	nucleus	NN
419	422	and	and	CC
423	431	displays	display	VBZ
432	439	binding	binding	NN
440	450	consistent	consistent	JJ
451	455	with	with	IN
456	459	two	two	CD
460	462	or	or	CC
463	467	more	more	JJR
468	473	sites	site	NNS
474	476	in	in	IN
477	480	the	the	DT
481	488	cytosol	cytosol	NN
489	493	from	from	IN
494	497	CEM	CEM	NNP
498	500	C7	c7	NN
501	506	cells	cell	NNS
507	508	(	(	(
508	509	a	a	DT
510	515	human	human	JJ
516	521	acute	acute	JJ
522	535	lymphoblastic	lymphoblastic	JJ
536	542	T-cell	t-cell	NN
543	547	line	line	NN
547	548	)	)	)
548	549	.	.	.

550	552	It	it	PRP
553	556	has	have	VBZ
557	567	previously	previously	RB
568	572	been	be	VBN
573	578	shown	show	VBN
579	583	that	that	IN
584	587	the	the	DT
588	593	lower	low	JJR
594	602	affinity	affinity	NN
603	608	class	class	NN
609	611	of	of	IN
612	617	sites	site	NNS
618	621	are	be	VBP
622	629	similar	similar	JJ
630	632	in	in	IN
633	641	affinity	affinity	NN
642	645	and	and	CC
646	650	site	site	NN
651	659	molarity	molarity	NN
660	662	to	to	TO
663	668	those	those	DT
669	679	recognized	recognize	VBN
680	682	by	by	IN
683	696	dexamethasone	dexamethasone	NN
696	697	.	.	.

698	701	The	the	DT
702	708	higher	high	JJR
709	717	affinity	affinity	NN
718	723	sites	site	NNS
724	728	bind	bind	VBP
729	732	CVZ	CVZ	NNP
733	737	with	with	IN
738	741	20-	20-	CD
742	744	to	to	TO
745	752	50-fold	50-fold	JJ
753	760	greater	great	JJR
761	769	affinity	affinity	NN
769	770	,	,	,
771	781	consistent	consistent	JJ
782	786	with	with	IN
787	790	CVZ	CVZ	NNP
790	792	’s	's	POS
793	801	enhanced	enhance	VBN
802	812	biological	biological	JJ
813	820	effects	effect	NNS
820	821	.	.	.

822	824	In	in	IN
825	831	mutant	mutant	JJ
832	840	leukemic	leukemic	JJ
841	846	cells	cell	NNS
847	856	resistant	resistant	JJ
857	859	to	to	TO
860	863	the	the	DT
864	869	lytic	lytic	JJ
870	877	effects	effect	NNS
878	880	of	of	IN
881	894	dexamethasone	dexamethasone	NN
894	895	,	,	,
896	899	CVZ	CVZ	NNP
900	904	both	both	DT
905	910	lyses	lysis	NNS
911	914	the	the	DT
915	920	cells	cell	NNS
921	924	and	and	CC
925	935	recognizes	recognize	VBZ
936	937	a	a	DT
938	944	single	single	JJ
945	950	class	class	NN
951	953	of	of	IN
954	959	sites	site	NNS
960	967	similar	similar	JJ
968	970	to	to	TO
971	974	the	the	DT
975	979	high	high	JJ
980	988	affinity	affinity	NN
989	993	site	site	NN
994	996	in	in	IN
997	1000	CEM	CEM	NNP
1001	1003	C7	C7	NNP
1004	1009	cells	cell	NNS
1009	1010	.	.	.

1011	1013	We	we	PRP
1014	1018	have	have	VBP
1019	1026	carried	carry	VBN
1027	1030	out	out	RP
1031	1042	experiments	experiment	NNS
1043	1045	to	to	TO
1046	1052	define	define	VB
1053	1056	the	the	DT
1057	1063	nature	nature	NN
1064	1066	of	of	IN
1067	1070	the	the	DT
1071	1077	higher	high	JJR
1078	1086	affinity	affinity	NN
1087	1090	CVZ	CVZ	NNP
1091	1098	binding	binding	NN
1099	1103	site	site	NN
1103	1104	.	.	.

1105	1107	We	we	PRP
1108	1111	now	now	RB
1112	1116	show	show	VBP
1117	1121	that	that	IN
1121	1122	:	:	:
1123	1124	1	1	LS
1124	1125	)	)	)
1126	1129	CVZ	CVZ	NNP
1130	1133	has	have	VBZ
1134	1138	more	more	JJR
1139	1143	than	than	IN
1144	1147	one	one	CD
1148	1155	binding	binding	NN
1156	1160	site	site	NN
1161	1163	in	in	IN
1164	1165	a	a	DT
1166	1172	second	second	JJ
1172	1173	,	,	,
1174	1185	independent	independent	JJ
1185	1186	,	,	,
1187	1193	B-cell	b-cell	NN
1194	1198	line	line	NN
1198	1199	,	,	,
1200	1204	IM-9	IM-9	NNP
1204	1205	;	;	:
1206	1207	2	2	LS
1207	1208	)	)	)
1209	1212	the	the	DT
1213	1231	antiglucocorticoid	antiglucocorticoid	JJ
1232	1234	RU	RU	NNP
1235	1240	38486	38486	CD
1241	1243	is	be	VBZ
1244	1248	able	able	JJ
1249	1251	to	to	TO
1252	1257	block	block	VB
1258	1262	both	both	DT
1263	1266	CVZ	CVZ	NNP
1266	1268	’s	's	POS
1269	1275	higher	high	JJR
1276	1279	and	and	CC
1280	1285	lower	low	JJR
1286	1294	affinity	affinity	NN
1295	1300	sites	site	NNS
1300	1301	;	;	:
1302	1303	3	3	LS
1303	1304	)	)	)
1305	1308	all	all	DT
1309	1311	of	of	IN
1312	1315	CVZ	CVZ	NNP
1315	1317	’s	's	POS
1318	1325	binding	bind	VBG
1326	1331	sites	site	NNS
1332	1335	are	be	VBP
1336	1338	on	on	IN
1339	1340	a	a	DT
1341	1348	protein	protein	NN
1349	1364	immunologically	immunologically	RB
1365	1382	indistinguishable	indistinguishable	JJ
1383	1387	from	from	IN
1388	1391	the	the	DT
1392	1397	human	human	JJ
1398	1400	GR	gr	NN
1400	1401	;	;	:
1402	1405	and	and	CC
1406	1407	4	4	LS
1407	1408	)	)	)
1409	1416	freshly	freshly	RB
1417	1425	isolated	isolate	VBN
1426	1432	clones	clone	NNS
1433	1435	of	of	IN
1436	1449	CVZ-resistant	cvz-resistant	JJ
1450	1455	cells	cell	NNS
1456	1460	have	have	VBP
1461	1465	lost	lose	VBN
1466	1469	all	all	DT
1470	1477	binding	bind	VBG
1478	1483	sites	site	NNS
1484	1487	for	for	IN
1488	1491	CVZ	CVZ	NNP
1491	1492	.	.	.

1493	1498	These	these	DT
1499	1503	data	datum	NNS
1504	1512	indicate	indicate	VBP
1513	1517	that	that	IN
1518	1521	CVZ	CVZ	NNP
1522	1524	is	be	VBZ
1525	1536	recognizing	recognize	VBG
1537	1540	two	two	CD
1541	1555	glucocorticoid	glucocorticoid	NN
1556	1563	binding	binding	NN
1564	1569	sites	site	NNS
1570	1572	on	on	IN
1573	1576	the	the	DT
1577	1582	human	human	JJ
1583	1585	GR	gr	NN
1586	1588	or	or	CC
1589	1590	a	a	DT
1591	1598	protein	protein	NN
1599	1603	very	very	RB
1604	1611	similar	similar	JJ
1612	1614	to	to	TO
1615	1617	it	it	PRP
1617	1618	.	.	.